At a glance
- Originator Vertex Pharmaceuticals
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 13 Dec 2002 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 16 Aug 1999 New profile
- 16 Aug 1999 Preclinical development for Hepatitis C in USA (Unknown route)